sciync

v0
Paper SpacePredictionsAI Sync
Your circlePrinciples
Join the waitlist
FeedProjectsNoosphere
All noemes
→

Trial · NCT02142283

NCT02142283

2018
New England Journal of Medicine
Sponsor: Stryker Neurovascular

Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

Raul G. Nogueira et al. · PI Tudor G Jovin, MD

Primary endpoint

Weighted Modified Rankin Scale (mRS) Score, Lead Co-Primary Efficacy Outcome

Population

Ischemic Stroke; n=206

doi:10.1056/NEJMoa1706442
Historical

1

Current

1

Future

1

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The DAWN trial's stated primary conclusion — Mechanical thrombectomy benefits selected large-vessel-occlusion stroke patients in the 6–24h window. — replicates in independent cohorts.

neurointerventional
Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of DAWN are confirming the original effect size in real-world data.

neurointerventional
Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, late-window thrombectomy (6–24h) will be explicitly endorsed by AHA/ASA guidelines as standard-of-care in qualifying LVO patients across at least 80% of US comprehensive stroke centers.

neurointerventional

P

71%